
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity is set to experience continued growth from its existing customer base and new hires in chief roles as demonstrated by the recent appointment of Matt Sonefeldt and Dr. Steve Zatz. However, challenges may arise with a decline in marketing spend from pharmaceutical companies due to a decreasing number of drugs under patent protection. Additionally, the company's F2027E guidance is lower than expected, with modest market growth and shorter-term spend commitments from customers due to macroeconomic concerns.
Bears say
Doximity is a promising digital health platform with recent successful partnerships and expansion efforts. However, their growth potential is hindered by market conditions and limited visibility into customer budgets, which has led analysts to lower revenue and EBITDA estimates. As a result, the company has been downgraded to Neutral and faces competition from other healthcare software companies like Veeva. Doximity and Veeva both face risks in retaining and attracting customers, which could affect their future growth prospects.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares